1. Signaling Pathways
  2. Autophagy
  3. Mitophagy

Mitophagy

Mitophagy is the selective degradation of mitochondria by autophagy.

Mitochondria are essential organelles that regulate cellular energy homeostasis and cell death. The removal of damaged mitochondria through autophagy, a process called mitophagy, is thus critical for maintaining proper cellular functions. Indeed, mitophagy has been recently proposed to play critical roles in terminal differentiation of red blood cells, paternal mitochondrial degradation, neurodegenerative diseases, and ischemia or drug-induced tissue injury.

Autophagy and mitophagy are important cellular processes that are responsible for breaking down cellular contents, preserving energy and safeguarding against accumulation of damaged and aggregated biomolecules.

Mitophagy Related Products (59):

Cat. No. Product Name Effect Purity
  • HY-19312
    3-Methyladenine Inhibitor 99.84%
    3-Methyladenine is a PI3K inhibitor. 3-Methyladenine is a widely used inhibitor of autophagy via its inhibitory effect on class III PI3K.
  • HY-10162
    Olaparib Activator 99.98%
    Olaparib (AZD2281;KU0059436) is a potent and oral PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively.
  • HY-15142
    Doxorubicin hydrochloride Activator 99.47%
    Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair.
  • HY-10256
    SB 203580 Activator 99.92%
    SB 203580 (RWJ 64809) is a selective and ATP-competitive p38 MAPK inhibitor. SB 203580 (RWJ 64809) inhibits SAPK2a/p38 and SAPK2b/p38β2, with IC50s of 50 nM and 500 nM, respectively. LCK, GSK3β and PKBα are also inhibited by SB 203580 (RWJ 64809), but the IC50s are 100-500-fold higher than that for SAPK2a/p38.
  • HY-17471A
    Metformin hydrochloride Activator 99.98%
    Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.
  • HY-115576
    P62-mediated mitophagy inducer Activator
    P62-mediated mitophagy inducer is a mitophagy regulator which activates mitophagy without recruiting Parkin or collapsing ΔΨm and retains activity in cells devoid of a fully functional PINK1/Parkin pathway.
  • HY-14648
    Dexamethasone Activator 99.86%
    Dexamethasone is a glucocorticoid receptor agonist.
  • HY-13417
    AICAR Inhibitor 99.92%
    AICAR is a cell-permeable AMP-activated protein kinase (AMPK) activator.
  • HY-16592
    Brefeldin A Inhibitor 99.79%
    Brefeldin A is a specific inhibitor of protein trafficking which blocks the protein transport from the endoplasmic reticulum to the Golgi complex.
  • HY-50856
    Ruxolitinib Activator 99.99%
    Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.
  • HY-10221
    Vorinostat Activator 99.90%
    Vorinostat is a potent and orally available inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC7 (Class II) and HDAC11 (Class IV ), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively.
  • HY-B0988
    Deferoxamine mesylate Activator >99.0%
    Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.
  • HY-13629
    Etoposide Activator 99.65%
    Etoposide (VP-16; VP-16-213), a chemotherapy medication used for the treatments of a number of types of cancer, inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. Etoposide arrests cell cycle in G2 and induces apoptosis.
  • HY-15886
    Mdivi-1 Inhibitor 98.75%
    Mdivi-1 is a selective dynamin-related protein 1 (Drp1) inhibitor. Mdivi-1 is a mitochondrial division/mitophagy inhibitor.
  • HY-10211
    Tanespimycin Inhibitor 99.03%
    Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90.
  • HY-16561
    Resveratrol Activator 98.90%
    Resveratrol (SRT 501), a natural polyphenol that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. It has a wide spectrum of targets including mTOR, JAK, β-amyloid. Resveratrol also is a specific SIRT1 activator.
  • HY-N0005
    Curcumin Activator 99.66%
    Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.
  • HY-B0075
    Melatonin Inhibitor 98.95%
    Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties.
  • HY-10255A
    Sunitinib Activator 99.66%
    Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively.
  • HY-50858
    Ruxolitinib phosphate Activator 99.89%
    Ruxolitinib phosphate is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.